Tollen v. Geron Corporation

CourtDistrict Court, N.D. California
DecidedApril 2, 2022
Docket3:20-cv-00547
StatusUnknown

This text of Tollen v. Geron Corporation (Tollen v. Geron Corporation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tollen v. Geron Corporation, (N.D. Cal. 2022).

Opinion

1 2 3 4 5 6 7 UNITED STATES DISTRICT COURT 8 NORTHERN DISTRICT OF CALIFORNIA 9 10 11 JULIA JUNGE and RICHARD JUNGE, on behalf of themselves and similarly situated 12 investors, No. C 20-00547-WHA 13 Plaintiffs, 14 v. ORDER RE MOTION TO CERTIFY CLASS, APPOINT CLASS 15 GERON CORPORATION and REPRESENTATIVES, AND JOHN A. SCARLETT, APPOINT CLASS COUNSEL 16 Defendants. 17 18 INTRODUCTION 19 In this PSLRA securities action, lead plaintiffs move to certify a class. They also move 20 for appointment as class representatives and for appointment of lead counsel. To the extent 21 stated below, the motion is GRANTED. 22 STATEMENT 23 A prior order detailed the facts of the operative complaint (Dkt. Nos. 103, 124). In brief, 24 court-appointed lead plaintiffs Julia and Richard Junge invested in defendant Geron 25 Corporation. At all material times, defendants Geron and its President and CEO John A. 26 Scarlett worked to develop a single drug, imetelstat. Defendants hoped that imetelstat could 27 1 improve quality of life and/or survival for patients with myelofibrosis, a cancer affecting bone 2 marrow (Amd. Compl. ¶¶ 51, 52). 3 The putative class period (March 19, 2018, through September 26, 2018) covered the late 4 stages of Geron’s phase-two clinical trial, which was titled IMbark. To conduct the trial, 5 Geron partnered with Janssen Biotech Inc. The companies sought to measure whether 6 imetelstat could improve certain health markers, known as study “endpoints.” Three of the 7 endpoints were total symptom score (TSS), complete and/or partial remission (CR/PR), and 8 spleen volume reduction (SVR). 9 Our prior order granted in part defendants’ motion to dismiss but let claims proceed as to 10 certain categories of statements (Dkt. No. 124 at 9–11). Specifically, Geron and Scarlett 11 allegedly warmed the market on Geron common stock by issuing optimistic statements about 12 IMbark’s TSS and CR/PR endpoints, when really the data disappointed. As alleged, the first 13 disclosure occurred March 19, 2018, whereupon it artificially inflated the price of Geron 14 common stock. Numerous other disclosures, too, allegedly inflated stock prices throughout the 15 class period. 16 The truth eventually came out, per the complaint. Geron revealed TSS and CR/PR data 17 after the market closed on September 26, 2018. Before the market opened the next day, 18 Janssen announced it would quit the partnership with Geron. These two disclosures therefore 19 shared the same “market date” of September 27 (Campisi Decl. Exh. A, n. 67, Exh. 7). Over 20 the two days that followed, Geron stock price plunged by approximately 70% (ibid.; Amd. 21 Compl. ¶¶ 14, 41). 22 Lead plaintiffs now move to certify a class under FRCP 23(a) and 23(b)(3) consisting of:

23 All persons who purchased Geron common stock during the period from March 19, 2018, to September 26, 2018, inclusive, and who 24 were damaged thereby (the “Class”).1 25 26 27 1 In support of this motion, lead plaintiffs submit an expert report by Chad Coffman, CFA, and 2 copies of SEC filings that contain some of the alleged misrepresentations. They also move to 3 appoint plaintiffs Julia and Richard Junge as class representatives and to appoint Kaplan Fox as 4 class counsel. Defendants oppose certification, arguing that predominance is not met as to 5 damages. This order follows full briefing and oral argument (Dkt. No. 141, Campisi Decl. ¶¶ 6 3, 4). 7 ANALYSIS 8 Certification under Rule 23(b)(3) is a two-step process. A plaintiff must first show that 9 the four prerequisites of Rule 23(a) are met: (1) the class is so numerous that joinder of all 10 members is impracticable; (2) questions of law or fact exist common to the class; (3) the claims 11 or defenses of the representative parties are typical of the claims or defenses of the class; and 12 (4) the representative parties will fairly and adequately protect the interests of the class. For a 13 damages class under Rule 23(b)(3), a plaintiff must establish “that the questions of law or fact 14 common to class members predominate over any questions affecting only individual members, 15 and that a class action is superior to other available methods for fairly and efficiently 16 adjudicating the controversy.” A plaintiff bears the burden of demonstrating that these 17 requirements are met. See Abdullah v. U.S. Sec. Assocs., Inc., 731 F.3d 952, 956–57 (9th Cir. 18 2013). 19 The Supreme Court has “cautioned that a court’s class-certification analysis must be 20 rigorous and may entail some overlap with the merits of the plaintiff’s underlying claim,” Wal– 21 Mart Stores, Inc. v. Dukes, 564 U.S. 338, 350 (2011) (cleaned up); however, “[m]erits 22 questions may be considered to the extent — but only to the extent — that they are relevant to 23 determining whether the Rule 23 prerequisites for class certification are satisfied.” Amgen Inc. 24 v. Conn. Ret. Plans and Tr. Funds, 568 U.S. 455, 464–65 (2013). 25 Defendants oppose class certification because, they argue, plaintiffs have failed to 26 propose a viable class-wide damages model. This order examines each requirement of the 27 class certification analysis to ensure that the putative class satisfies the requirements of Rule 1. RULE 23(a). 1 A. NUMEROSITY. 2 At all material times, Geron common stock was registered and traded on the NASDAQ 3 stock exchange, with more than 173 million shares outstanding; defendants admit that Geron 4 sold over ten million shares during the class period; and a FINRA registered broker sold Geron 5 stock to at least 100 unique account holders during the class period (Campisi Decl. Exh. A ¶¶ 6 26–30, 67; Exh. B at 13–15). Thus, “[j]oinder of all members is impracticable.” FRCP 23(a). 7 B. COMMONALITY. 8 To show commonality, a plaintiff “need not show . . . that every question in the case, or 9 even a preponderance of questions, is capable of class wide resolution. So long as there is 10 even a single common question, a would-be class can satisfy the commonality requirement of 11 Rule 23(a)(2).” Parsons v. Ryan, 754 F.3d 657, 675 (9th Cir. 2014) (cleaned up). Here, 12 plaintiffs’ allegations that the same public misrepresentations in Securities and Exchange 13 Commission (SEC) filings and earnings calls defrauded investors and that the investors 14 suffered similar losses as a result fulfill Rule 23(a)’s commonality requirement. Even if 15 individual damages calculations ultimately will differ, it appears that the artificial inflation per 16 share (if any) will be the same for each class member. 17 C. TYPICALITY. 18 Typicality suffices if “the claims or defenses of the representative parties are typical of 19 the claims or defenses of the class.” FRCP 23(a)(3). “Under the rule’s permissive standards, 20 representative claims are ‘typical’ if they are reasonably co-extensive with those of absent 21 class members; they need not be substantially identical.” Hanlon v. Chrysler Corp., 150 F.3d 22 1011, 1020 (9th Cir. 1998). A district court cannot, however, certify a class if a putative class 23 representative is subject to “unique defenses which threaten to become the focus of the 24 litigation.” Hanon v. Dataproducts Corp., 976 F.2d 497, 508 (9th Cir. 1992). In the instant 25 action, the surviving alleged misrepresentations and subsequent disclosures caused the Junges, 26 and absent class members alike, to suffer financial loss.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Affiliated Ute Citizens of Utah v. United States
406 U.S. 128 (Supreme Court, 1972)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Wolin v. Jaguar Land Rover North America, LLC
617 F.3d 1168 (Ninth Circuit, 2010)
Schleicher v. Wendt
618 F.3d 679 (Seventh Circuit, 2010)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Ellis v. Costco Wholesale Corp.
657 F.3d 970 (Ninth Circuit, 2011)
Cammer v. Bloom
711 F. Supp. 1264 (D. New Jersey, 1989)
Victor Parsons v. Charles Ryan
754 F.3d 657 (Ninth Circuit, 2014)
Muhammed Abdullah v. U.S. Security Associates, Inc.
731 F.3d 952 (Ninth Circuit, 2013)
Howard v. Liquidity Services, Inc.
322 F.R.D. 103 (District of Columbia, 2017)
Lentell v. Merrill Lynch & Co.
396 F.3d 161 (Second Circuit, 2005)
Krogman v. Sterritt
202 F.R.D. 467 (N.D. Texas, 2001)
In re Diamond Foods, Inc., Securities Litigation
295 F.R.D. 240 (N.D. California, 2013)
In re Barrick Gold Securities Litigation
314 F.R.D. 91 (S.D. New York, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Tollen v. Geron Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tollen-v-geron-corporation-cand-2022.